共 45 条
[1]
Thorpe KE(2018)Antibiotic-resistant infection treatment costs have doubled since 2002, now exceeding USD2 billion annually Health Aff Proj Hope 37 662-669
[2]
Joski P(2020)Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis PLoS ONE 15 1-327
[3]
Johnston KJ(2020)Infectious diseases society of america antimicrobial resistant treatment guidance: gram-negative bacterial infections Clin Infect Dis. 10.1093/cid/ciaa1478 15 1-298
[4]
Serra-Burriel M(2020)Assessment of data supporting the efficacy of new antibiotics for treating infections caused by multidrug-resistant bacteria Clin Infect Dis. 18 318-55
[5]
Keys M(2018)Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis Lancet Infect Dis. 18 286-400
[6]
Campillo-Artero C(2020)Critical analysis of antibacterial agents in clinical development Nat Rev Microbiol. 52 e18-1181
[7]
Tamma PD(2011)Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Clin Infect Dis. 18 391-undefined
[8]
Aitken SL(2018) infections in adults and children Lancet Infect Dis. 20 1172-undefined
[9]
Bonomo RA(2020)Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial Lancet Infect Dis. 6 344-undefined
[10]
Mathers AJ(2020)Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Lancet Infect Dis 34 1-undefined